Compare Gilead Sciences, Inc. (GILD) vs Invesco Preferred ETF (PGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Invesco Preferred ETF — how do they compare? Gilead Sciences, Inc. trades at $147 (market cap $182.09B), while Invesco Preferred ETF trades at $10.04 (market cap $3.64B). The key difference: Gilead Sciences, Inc. is far larger — about 50× Invesco Preferred ETF's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Invesco Preferred ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Invesco Preferred ETF for 94 Days on average.
| GILD | PGX | |
|---|---|---|
Market Cap | $182.09B | $3.64B |
Volume | 4,960,247 | 6,969,114 |
Sector | Health | — |
52-Week High | $155.80 | $11.61 |
52-Week Low | $116.74 | $9.97 |
Typical Hold Time | 111 Days | 94 Days |
Enterprise Value | $205.15B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, up 1.99% with bullish technical signals and strong analyst support. The stock shows mixed fundamentals with a P/E of 17.84 and robust gross margins of 79.59%, though recent net income margin turned negative at -10.64%. Recent quarterly earnings beat expectations, and the company announced significant HIV prevention partnerships expanding access to lenacapavir across Latin America.
Outlook remains positive with 65% analyst buy ratings and $151.14 consensus target, though investors face risks from negative profitability metrics and increased investing outflows. The stock's current position near pivot point resistance at $147 suggests potential for breakout if earnings momentum continues.
PGX trades at $9.97, down 0.89% with a bearish technical signal from moving averages despite oversold RSI readings. The stock shows identical support and resistance at $10, indicating consolidation. Recent dividend payments of $0.06 were declared for July and September 2026, providing income appeal. Financial ratios including P/E, P/S, and ROE are unavailable in current data, limiting fundamental visibility.
The outlook remains cautious due to bearish technical momentum and lack of current financial metrics. Income investors may find dividend payments attractive, but absence of earnings data and weak price action suggest near-term pressure. Key risks include undefined profitability and competitive challenges in the preferred ETF space highlighted by recent media coverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Invesco Preferred ETF
The fund generally will invest at least 80% of its total assets in the components of the index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC selects securities for the index, which is a market capitalization-weighted index designed to measure the performance of the fixed rate US dollar-denominated preferred securities market.
Read more on PGX →
